Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer.

Frontiers in oncology·2026
Same author

Trends in Neoadjuvant Pembrolizumab Use in Triple-Negative Breast Cancer.

American journal of clinical oncology·2026
Same author

One Size Fits All?

International journal of radiation oncology, biology, physics·2025
Same author

Neoadjuvant Chemotherapy and Immunotherapy for Estrogen Receptor-Positive Human Epidermal Growth Factor 2-Negative Breast Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2024
Same author

Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients With Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis.

HemaSphere·2023
Same author

Nailing the Clavicular Head: Assuring Adequate Coverage of the Medial/Inferior Aspect of the Supraclavicular Space in Patients Receiving Regional Nodal Radiation Therapy for Breast Cancer.

Practical radiation oncology·2023
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Jan 9, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K

How does biology affect local therapy decisions?

Thomas A Buchholz1

  • 1From the Division of Radiation Oncology, Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|January 24, 2014
PubMed
Summary
This summary is machine-generated.

Breast cancer treatment outcomes vary by biologic subtype. Radiation therapy shows excellent results for ER-positive, HER2/neu-negative breast cancer, but may offer less benefit for triple-negative disease.

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K

Related Experiment Videos

Last Updated: Jan 9, 2026

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids
08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.5K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.9K
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

14.8K

Area of Science:

  • Oncology
  • Genetics
  • Medical research

Background:

  • Breast cancer is a diverse disease with prognosis and treatment response influenced by receptor status.
  • Estrogen/progesterone receptor (ER/PR) and HER2/neu status are key determinants of breast cancer outcomes.
  • Receptor status also impacts the effectiveness of local-regional therapies, including radiation.

Purpose of the Study:

  • To analyze the impact of breast cancer biologic subtype on local-regional therapy outcomes.
  • To highlight existing data on radiation therapy efficacy based on ER/PR and HER2/neu status.
  • To propose future research directions for local-regional therapies tailored to breast cancer subtypes.

Main Methods:

  • Review of existing data correlating breast cancer biologic subtypes with treatment outcomes.
  • Analysis of studies evaluating radiation therapy in different breast cancer subtypes.
  • Discussion of clinical data regarding local-regional recurrence rates based on receptor status.

Main Results:

  • Patients with ER-positive, HER2/neu-negative breast cancer demonstrate excellent outcomes with radiation therapy.
  • Radiation therapy is effective as part of breast-conservative therapy (BCT) and post-mastectomy treatment in this subgroup.
  • The proportional benefit of radiation in reducing local-regional recurrences may be less pronounced in triple-negative breast cancer.

Conclusions:

  • Breast cancer biologic subtype significantly influences the effectiveness of local-regional therapies like radiation.
  • Tailoring radiation strategies based on ER/PR and HER2/neu status is crucial for optimizing patient outcomes.
  • Further research is needed to define optimal local-regional treatment approaches for all breast cancer subtypes, particularly triple-negative disease.